Coherus Biosciences Inc (OQ:CHRS)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 333 Twin Dolphin Dr Ste 600
REDWOOD CITY CA 94065-1442
Tel: N/A
IR: See website
Key People
Dennis M. Lanfear
Chairman of the Board, President, Chief Executive Officer
Jean-Frederic Viret
Chief Financial Officer
Vincent R. Anicetti
Chief Operating Officer
Vladimir Vexler
Chief Scientific Officer
Thomas Fitzpatrick
Chief Legal Officer
Business Overview
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.
Financial Overview
For the three months ended 31 March 2020, Coherus Biosciences Inc revenues increased from $37.1M to $116.2M. Net income totaled $35.6M vs. loss of $20M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Stock-based Compensation in R&D decrease of 2% to $3.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.29 to $0.50.
Employees: 296 as of Mar 31, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $1,326M as of Jun 30, 2020
Annual revenue (TTM): $435.15M as of Jun 30, 2020
EBITDA (TTM): $168.51M as of Jun 30, 2020
Net annual income (TTM): $145.41M as of Jun 30, 2020
Free cash flow (TTM): $95.55M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 71,470,437 as of Jul 31, 2020
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.